Oxford University Gearing Up To Conduct Pandemic Vaccine Trials In India
In a piece of good news, Oxford University spoke its heart on the vaccine trial for the pandemic and said the preliminary trials of the vaccine conducted on the volunteers displayed a positive impact and the University is optimistic about coming up with a potential vaccine for the ongoing pandemic.
The collegiate research university Oxford has joined hands with the renowned British-Swedish multinational pharmaceutical company AstraZeneca PLC to develop a potential vaccine.
On the other hand, the famous university which is not leaving any stone unturned to develop a vaccine as soon as possible announced that the vaccine trials will be kickstarted in India soon.
To conduct the clinical trials, Oxford University will join forces with the manufacturer of the immunobiological drugs Serum Institute of India (SII), which is based out of Pune city.
With the vaccine trials speeding up, itis expected that the vaccine might be out very soon. Hopefully, after the vaccine is made available, SII would help a lending hand in manufacturing the vaccine on a large scale.
As the clinical trial requires a license, the SII is gearing up to seek a license from the apex clinical body, Drug Controller General of India (DCGI) to go ahead with the clinical trials.
The collegiate research university Oxford has joined hands with the renowned British-Swedish multinational pharmaceutical company AstraZeneca PLC to develop a potential vaccine.
On the other hand, the famous university which is not leaving any stone unturned to develop a vaccine as soon as possible announced that the vaccine trials will be kickstarted in India soon.
To conduct the clinical trials, Oxford University will join forces with the manufacturer of the immunobiological drugs Serum Institute of India (SII), which is based out of Pune city.
With the vaccine trials speeding up, itis expected that the vaccine might be out very soon. Hopefully, after the vaccine is made available, SII would help a lending hand in manufacturing the vaccine on a large scale.
As the clinical trial requires a license, the SII is gearing up to seek a license from the apex clinical body, Drug Controller General of India (DCGI) to go ahead with the clinical trials.